Answers are grounded in this paper and cite their sources.
A review discussing direct oral anticoagulants as alternatives to vitamin K antagonists in patients with atrial fibrillation or venous thromboembolism.
Rivaroxaban, apixaban and dabigatran are now commonly used as alternatives to vitamin K antagonist therapy (e.g., warfarin) for patients with atrial fibrillation, and for the treatment and prevention of venous thromboembolism. Dabigatran is a direct thrombin inhibitor, whereas apixaban and
No takes yet. Share an insight, caveat, or question.
Wood et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: